HCW Biologics Inc. (HCWB)
HCWB moved a median of -0.10% 30 minutes after news, and -0.44% by the close. How HCWB actually reacts to news — the realized, point-in-time move the market made, measured across 230 labeled events over the last three years with zero look-ahead.
HCWB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 211 |
| 30-min | -0.10% | 46% | 219 |
| 60-min | -0.52% | 42% | 222 |
| to close | -0.44% | 46% | 230 |
| Middle 50% of HCWB reactions | -2.91% to +2.45% |
|---|---|
| Median reaction (30-min) | -0.10% |
| Measured reactions | 230 |
Half of all HCW Biologics Inc. news events land between -2.91% and +2.45% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when HCWB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to HCWB's baseline. Nothing else.
Recent HCWB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form EFFECT HCW Biologics Inc. | SEC filing · Form EFFECT | SEC EDGAR | +5.38% | -3.08% | |
| HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors | Press release | GlobeNewswire | +2.56% | +2.56% | |
| Form D HCW Biologics Inc. | SEC filing · Form D | SEC EDGAR | — | -1.29% | |
| Form S-1 HCW Biologics Inc. | SEC filing · Form S-1 | SEC EDGAR | -4.27% | +0.00% | |
| Form DEF 14A HCW Biologics Inc. For: Oct 01 | SEC filing · Form DEF | SEC EDGAR | — | -1.74% | |
| Form 8-K HCW Biologics Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -1.18% | +17.75% | |
| HCW Biologics Announces Pricing of $1.5 Million Private Placement | Press release | GlobeNewswire | -1.18% | +17.75% | |
| Form 8-K HCW Biologics Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | +0.41% | |
| Form PRER14A HCW Biologics Inc. | SEC filing · Form PRER14A | SEC EDGAR | -0.37% | +0.41% | |
| Form 8-K HCW Biologics Inc. For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | -1.59% | -0.40% | |
| Form PRE 14A HCW Biologics Inc. For: Sep 04 | SEC filing · Form PRE | SEC EDGAR | -1.59% | -0.40% | |
| HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells | Press release | GlobeNewswire | -1.59% | -0.40% | |
| HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment | Press release | GlobeNewswire | +2.54% | -5.23% | |
| Form EFFECT HCW Biologics Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.85% | -1.71% | |
| Form S-1/A HCW Biologics Inc. | SEC filing · Form S-1 | SEC EDGAR | -8.91% | -0.28% | |
| HCW Biologics’ TGF-ß Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells | Press release | GlobeNewswire | +1.30% | +12.55% | |
| Form S-1 HCW Biologics Inc. | SEC filing · Form S-1 | SEC EDGAR | -0.85% | -9.40% | |
| Form 10-Q HCW Biologics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.12% | +0.00% | |
| Form 10-Q/A HCW Biologics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.94% | +1.13% | |
| Form 8-K HCW Biologics Inc. For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | -1.36% | -12.70% | |
| Form 8-K HCW Biologics Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | -1.11% | |
| HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results | Press release | GlobeNewswire | -3.39% | -4.46% | |
| Form D HCW Biologics Inc. | SEC filing · Form D | SEC EDGAR | +0.76% | +3.02% | |
| Form 8-K HCW Biologics Inc. For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +2.35% | +23.53% | |
| HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering | Press release | GlobeNewswire | -6.06% | +2.79% | |
| HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027 | Press release | GlobeNewswire | -2.14% | -11.93% | |
| Form POS AM HCW Biologics Inc. | SEC filing · Form POS | SEC EDGAR | +0.00% | -5.58% | |
| Form 8-K HCW Biologics Inc. For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | -3.09% | -5.76% | |
| Form 8-K HCW Biologics Inc. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | -10.57% | |
| HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter | Press release | GlobeNewswire | -0.36% | -10.57% | |
| Form 8-K HCW Biologics Inc. For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +0.40% | +8.86% | |
| HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 | Press release | GlobeNewswire | +0.40% | +8.86% | |
| Form EFFECT HCW Biologics Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.43% | +8.41% | |
| Form S-1/A HCW Biologics Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.96% | +4.81% | |
| Form 8-K HCW Biologics Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +3.60% | +2.70% | |
| HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata | Press release | GlobeNewswire | +3.60% | +2.70% | |
| Form 8-K HCW Biologics Inc. For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +3.60% | +2.70% | |
| Form D HCW Biologics Inc. | SEC filing · Form D | SEC EDGAR | +1.44% | -15.11% | |
| Form S-1 HCW Biologics Inc. | SEC filing · Form S-1 | SEC EDGAR | +1.33% | -1.40% | |
| Form 8-K HCW Biologics Inc. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -5.69% | -1.90% | |
| Form 8-K HCW Biologics Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -6.06% | -26.52% | |
| HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen | Press release | GlobeNewswire | -6.06% | -26.52% | |
| Form 8-K HCW Biologics Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +1.86% | -10.25% | |
| HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules | Press release | GlobeNewswire | +17.28% | +35.08% | |
| Form POS AM HCW Biologics Inc. | SEC filing · Form POS | SEC EDGAR | +0.02% | +16.52% | |
| Form 10-Q HCW Biologics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +17.27% | +10.91% | |
| Form 8-K HCW Biologics Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +17.27% | +10.91% | |
| HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies | Press release | GlobeNewswire | +1.08% | -4.67% | |
| HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | Press release | GlobeNewswire | +17.27% | +10.91% | |
| Form POS AM HCW Biologics Inc. | SEC filing · Form POS | SEC EDGAR | +1.08% | -4.67% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the HCWB section they belong to.
Where else HCWB is measured.
HCWB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is HCW Biologics Inc.'s median reaction calculated?
Every labeled HCWB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 230 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of HCWB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does HCWB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.